Jounce Therapeutics Appoints Deborah Law, D.Phil., to Chief Scientific Officer

CAMBRIDGE, Mass.--()--Jounce Therapeutics, Inc., a company focused on the discovery and development of novel cancer immunotherapies coupled to patient selection strategies, today announced the appointment of Deborah Law, D. Phil., to the position of chief scientific officer. Dr. Law brings to Jounce nearly two decades of experience in biologics drug discovery and development, particularly in the fields of oncology and immunology.

Dr. Law joins Jounce from Merck, where she most recently served as vice president of Therapy Area Biology for Immunology, Oncology and Immunomodulators. In this role, she was responsible for bringing cancer immunotherapy compounds from discovery to the clinic.

“Deb’s background in immune oncology and ability to drive new candidates into development is a perfect fit for Jounce and I am thrilled to have her as part of our team,” said Richard Murray Ph.D., chief executive officer of Jounce. “In addition to her subject matter expertise, her track record of executive level leadership in both small and large companies will be of substantial value as we continue to build Jounce.”

“I am delighted to join Jounce during this exciting time for the cancer immunotherapy area,” said Dr. Law. “I am particularly impressed with the company’s core translational science platform, which couples new immunotherapies with patient selection strategies, a fundamental next step for the entire field. I look forward to working with the scientific team at Jounce and building off the company’s strong translational science foundation to bring the right immune oncology therapies to the right patients.”

Prior to Merck, Dr. Law served as the chief scientific officer for Ablynx n.v. and held various research positions in biotechnology companies including PDL Biopharma, EOS Biotechnology and Cor Therapeutics. Dr. Law received her B.Sc. in immunology from Glasgow University, her D. Phil. in immunology from Oxford University and pursued postdoctoral research at University of California San Francisco.

About Jounce Therapeutics

Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing novel cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce integrates translational science insights to select the right targets and patient populations leading to clinical trials with higher probability of success and rapid proof-of-concept. The company is advancing programs that leverage contributions from its world-class founders as well as knowledge acquired from Jounce’s translational science platform to create a sustainable “discovery to human proof-of-concept” product engine with the potential to drive significantly more durable responses to treatment. Founded by world leaders in tumor immunology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures. For more information, please visit www.jouncetx.com.

Contacts

Pure Communications, Inc.
Katie Engleman, 910-509-3977
Katie@purecommunicationsinc.com

Contacts

Pure Communications, Inc.
Katie Engleman, 910-509-3977
Katie@purecommunicationsinc.com